NCT01458392View on ClinicalTrials.gov

Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

June 30, 2015

Study Completion Date

September 30, 2015

Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
BIOLOGICAL

Dalantercept

Subcutaneous dose of dalantercept once every 3 weeks.

Trial Locations (8)

Unknown

Acceleron Investigative Site, Aurora

Acceleron Investigative Site, Atlanta

Acceleron Investigative Site, Boston

Acceleron Investigative Site, Detroit

Acceleron Investigative Site, New York

Acceleron Investigative Site, Philadelphia

Acceleron Investigative Site, San Antonio

Acceleron Investigative Site, Salt Lake City

All Listed Sponsors
lead

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

INDUSTRY

NCT01458392 - Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck | Biotech Hunter | Biotech Hunter